Crestline Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $9.43M | Buy |
|
|||||
|
2024
Q3 | $8.25M | Buy |
|
|||||
|
2024
Q2 | $2.94M | Buy |
|
|||||
|
2024
Q1 | $2.47M | Buy |
|
|||||
|
2023
Q4 | $2.18M | Sell |
|
|||||
|
2023
Q3 | $1.95M | Buy |
|
|||||
|
2023
Q2 | $2.35M | Buy |
|
|||||
|
2023
Q1 | $2.01M | Buy |
|
|||||
|
2022
Q4 | $1.63M | Buy |
|
|||||
|
2022
Q3 | $1.53M | Buy |
|
|||||
|
2022
Q2 | $1.17M | Sell |
|
|||||
|
2022
Q1 | $1.1M | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $246K | Sell |
|
|||||
|
2018
Q1 | $522K | Sell |
|
|||||
|
2017
Q4 | $728K | Buy |
|
|||||
|
2017
Q3 | $626K | Sell |
|
|||||
|
2017
Q2 | $773K | Buy |
|